A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Clinical trial NCT02918331 · COMPLETED
Trial details
- NCT number
- NCT02918331
- Sponsor
- Janssen Pharmaceutical K.K.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2017-10-01
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.